arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Travere Therapeutics, Inc.

TVTX
$60.28 ▼ -2.56 (-4.07%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
64 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Travere Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $5.6B
Dividend Yield
Revenue Growth 48.2%
Op. Margin 2.3%
ROIC 16.0%
FCF / Share $0.62
Trailing P/E
Price / Book 231.5x
FCF Yield 1.0%
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

64-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$169.58M
↑ +48.2%
Net Income Profit after all expenses
$-34.80M
↓ -172.8%
Operating Margin Operating profit as % of sales
2.3%
↑ +108.0% 13th
FCF / Share Free cash flow per share
$0.62
↑ +241.4%
Long-Term Debt Long-term obligations
$46.00M
↓ -49.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
29
Returns
27
Financial Health
34
Cash Quality
8

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 16 years · 64 quarters